Cancer Risk With Topical Pimecrolimus and Tacrolimus For Atopic Dermatitis: Systematic Review and Bayesian Meta-Analysis

Atopic dermatitis (AD) affects millions worldwide and is effectively managed by topical treatments, including the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus. In 2005 and 2011, the FDA released reviews associating TCIs with theoretical cancer risk, albeit uncertain. We systematically reviewed the cancer risk in patients with AD exposed to TCIs.

Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Alexandro Chu, Niveditha Devasenapathy, Melanie Wong, Archita Srivastava, Clement Lin, Renata Ceccacci, Margaret MacDonald, Derek Chu, for the AAAAI/ACAAI Joint Task Force on Practice Parameters Source Type: research